ARCT
Arcturus Therapeutics Holdings Inc. (NASDAQ)
Healthcare — Biotechnology
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Price History
Fundamentals
| Market Cap | $191.00M |
| P/E Ratio (TTM) | - |
| Forward P/E | -1.68 |
| EPS (TTM) | $-2.83 |
| Dividend Yield | - |
| Profit Margin | -143.80% |
| Revenue Growth | -93.00% |
| ROE | -37.01% |
| Debt/Equity | 12.54 |
| Recommendation | None |
| Analyst Target | $19.89 |
| Analysts | 9 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 40.1 |
| Beta | 2.35 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $24.17 |
| 52-Week Low | $5.85 |
| 50-Day Avg | $7.79 |
| 200-Day Avg | $9.45 |
| Avg Volume | 467.4K |
| Volume | 323.3K |
Performance Analysis
NEUTRALARCT presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jun 30, 2026 21:07 UTC
Back to Screener Export Report